Connection

Daniel Judge to Middle Aged

Back to Details
This is a "connection" page, showing publications Daniel Judge has written about Middle Aged.
Daniel Judge
Connection Strength
1.071
Middle Aged
  1. Long-Term Efficacy and Safety of ARRY-371797 (PF-07265803) in Patients With Lamin A/C-Related Dilated Cardiomyopathy. Am J Cardiol. 2022 11 15; 183:93-98.
    View in: PubMed
    Score: 0.061
  2. Genetic Dilated Cardiomyopathy Due to TTN Variants Without Known Familial Disease. Circ Genom Precis Med. 2020 12; 13(6):e003082.
    View in: PubMed
    Score: 0.054
  3. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
    View in: PubMed
    Score: 0.052
  4. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid?Cardiomyopathy. J Am Coll Cardiol. 2019 07 23; 74(3):285-295.
    View in: PubMed
    Score: 0.048
  5. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid. 2017 Jun; 24(2):92-95.
    View in: PubMed
    Score: 0.042
  6. Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovasc Res. 2017 01; 113(1):102-111.
    View in: PubMed
    Score: 0.041
  7. Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. J Card Fail. 2017 Apr; 23(4):340-344.
    View in: PubMed
    Score: 0.041
  8. Absence of a Primary Role for SCN10A Mutations in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. J Cardiovasc Transl Res. 2016 Feb; 9(1):87-9.
    View in: PubMed
    Score: 0.039
  9. Shared desmosome gene findings in early and late onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Transl Res. 2010 Dec; 3(6):663-73.
    View in: PubMed
    Score: 0.027
  10. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA. 2009 Dec 09; 302(22):2471-6.
    View in: PubMed
    Score: 0.025
  11. Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet. 2009 Oct; 2(5):428-35.
    View in: PubMed
    Score: 0.024
  12. Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2006 Oct 03; 48(7):1416-24.
    View in: PubMed
    Score: 0.020
  13. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006 Apr 04; 113(13):1641-9.
    View in: PubMed
    Score: 0.020
  14. Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med. 2005 Jan; 2(1):53-7.
    View in: PubMed
    Score: 0.018
  15. Reversible dilated cardiomyopathy associated with glucagonoma. Heart. 2004 Jul; 90(7):e44.
    View in: PubMed
    Score: 0.017
  16. Knowledge of Genome Sequencing and Trust in Medical Researchers Among Patients of Different Racial and Ethnic Groups With Idiopathic Dilated Cardiomyopathy. JAMA Cardiol. 2023 01 01; 8(1):33-42.
    View in: PubMed
    Score: 0.016
  17. The response to cardiac resynchronization therapy in LMNA cardiomyopathy. Eur J Heart Fail. 2022 04; 24(4):685-693.
    View in: PubMed
    Score: 0.015
  18. Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA. 2022 02 01; 327(5):454-463.
    View in: PubMed
    Score: 0.015
  19. Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation. 2021 11 16; 144(20):1600-1611.
    View in: PubMed
    Score: 0.014
  20. Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical Features. Circ Genom Precis Med. 2021 04; 14(2):e003097.
    View in: PubMed
    Score: 0.014
  21. Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. Am Heart J. 2021 03; 233:122-131.
    View in: PubMed
    Score: 0.014
  22. Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Heart Assoc. 2020 02 04; 9(3):e013695.
    View in: PubMed
    Score: 0.013
  23. FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy. J Med Genet. 2020 04; 57(4):254-257.
    View in: PubMed
    Score: 0.013
  24. SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. Heart Lung Circ. 2020 Aug; 29(8):1241-1246.
    View in: PubMed
    Score: 0.012
  25. Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circ Genom Precis Med. 2019 08; 12(8):e002467.
    View in: PubMed
    Score: 0.012
  26. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019 06 14; 40(23):1850-1858.
    View in: PubMed
    Score: 0.012
  27. Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid. 2018 Sep; 25(3):174-179.
    View in: PubMed
    Score: 0.012
  28. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379(11):1007-1016.
    View in: PubMed
    Score: 0.012
  29. Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). J Cardiovasc Electrophysiol. 2018 07; 29(7):1004-1009.
    View in: PubMed
    Score: 0.011
  30. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017 Sep; 24(3):194-204.
    View in: PubMed
    Score: 0.011
  31. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol. 2017 Jul; 82(1):44-56.
    View in: PubMed
    Score: 0.011
  32. Giant Ring Mitochondria in a Patient With Heart Failure and Cerebral White Matter Disease Resulting From an MT-TL1 Mitochondrial Gene Mutation. J Card Fail. 2017 Aug; 23(8):652-655.
    View in: PubMed
    Score: 0.011
  33. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications. J Am Heart Assoc. 2017 Jun 06; 6(6).
    View in: PubMed
    Score: 0.011
  34. Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation. Heart Rhythm. 2017 06; 14(6):883-891.
    View in: PubMed
    Score: 0.010
  35. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant. 2017 Apr; 36(4):380-385.
    View in: PubMed
    Score: 0.010
  36. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 07 12; 68(2):161-72.
    View in: PubMed
    Score: 0.010
  37. Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes. J Card Fail. 2016 07; 22(7):583-5.
    View in: PubMed
    Score: 0.010
  38. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm. 2016 Jan; 13(1):199-207.
    View in: PubMed
    Score: 0.009
  39. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J. 2016 Mar 01; 37(9):755-63.
    View in: PubMed
    Score: 0.009
  40. Fluctuating creatinine in the cardiac unit. Clin Chim Acta. 2015 Jul 20; 447:52-4.
    View in: PubMed
    Score: 0.009
  41. Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. J Cardiovasc Transl Res. 2015 Jun; 8(4):264-8.
    View in: PubMed
    Score: 0.009
  42. Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet. 2015 Jun; 8(3):437-46.
    View in: PubMed
    Score: 0.009
  43. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015 Mar; 8(2):117-27.
    View in: PubMed
    Score: 0.009
  44. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015 Apr 07; 36(14):847-55.
    View in: PubMed
    Score: 0.009
  45. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2015 Apr; 12(4):716-25.
    View in: PubMed
    Score: 0.009
  46. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc. 2014 Dec; 3(6):e001471.
    View in: PubMed
    Score: 0.009
  47. Yield of serial evaluation in at-risk family members of patients with ARVD/C. J Am Coll Cardiol. 2014 Jul 22; 64(3):293-301.
    View in: PubMed
    Score: 0.009
  48. Novel and highly lethal NKX2.5 missense mutation in a family with sudden death and ventricular arrhythmia. Pediatr Cardiol. 2014 Oct; 35(7):1206-12.
    View in: PubMed
    Score: 0.009
  49. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014 Apr; 7(2):230-6.
    View in: PubMed
    Score: 0.008
  50. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. Circulation. 2014 Mar 11; 129(10):1092-103.
    View in: PubMed
    Score: 0.008
  51. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec; 6(6):1011-20.
    View in: PubMed
    Score: 0.008
  52. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2013 Nov; 10(11):1661-8.
    View in: PubMed
    Score: 0.008
  53. Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol. 2013 Dec; 24(12):1311-20.
    View in: PubMed
    Score: 0.008
  54. Malignant arrhythmogenic right ventricular dysplasia/cardiomyopathy with a normal 12-lead electrocardiogram: a rare but underrecognized clinical entity. Heart Rhythm. 2013 Oct; 10(10):1484-91.
    View in: PubMed
    Score: 0.008
  55. Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2013 Nov 05; 62(19):1772-9.
    View in: PubMed
    Score: 0.008
  56. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. Circ Arrhythm Electrophysiol. 2013 Jun; 6(3):569-78.
    View in: PubMed
    Score: 0.008
  57. The variable natural history of idiopathic dilated cardiomyopathy. Isr Med Assoc J. 2012 Nov; 14(11):666-71.
    View in: PubMed
    Score: 0.008
  58. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 2013 May-Jun; 22(3):189-94.
    View in: PubMed
    Score: 0.008
  59. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail. 2012 Apr; 18(4):296-303.
    View in: PubMed
    Score: 0.007
  60. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2012 Jun; 9(6):961-7.
    View in: PubMed
    Score: 0.007
  61. Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2012 Jan 17; 59(3):289-90.
    View in: PubMed
    Score: 0.007
  62. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011 Sep 27; 58(14):1485-96.
    View in: PubMed
    Score: 0.007
  63. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol. 2011 Jun 07; 57(23):2317-27.
    View in: PubMed
    Score: 0.007
  64. The change in B-type natriuretic peptide levels over time predicts significant rejection in cardiac transplant recipients. J Heart Lung Transplant. 2009 Jul; 28(7):704-9.
    View in: PubMed
    Score: 0.006
  65. Morphologic variants of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy a genetics-magnetic resonance imaging correlation study. J Am Coll Cardiol. 2009 Apr 14; 53(15):1289-99.
    View in: PubMed
    Score: 0.006
  66. Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2009 Jun; 6(6):769-75.
    View in: PubMed
    Score: 0.006
  67. Familial hypertrophic cardiomyopathy associated with cardiac beta-myosin heavy chain and troponin I mutations. Pediatr Cardiol. 2008 Jul; 29(4):846-50.
    View in: PubMed
    Score: 0.006
  68. Extensive cardiac allograft vasculitis and concurrent fat necrosis 6 years after orthotopic heart transplantation. J Heart Lung Transplant. 2007 Nov; 26(11):1212-6.
    View in: PubMed
    Score: 0.005
  69. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007 Jul 31; 50(5):432-40.
    View in: PubMed
    Score: 0.005
  70. Intracardiac giant cells after left ventricular assist device placement. J Heart Lung Transplant. 2007 Apr; 26(4):417-20.
    View in: PubMed
    Score: 0.005
  71. The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm. 2006 Apr; 3(4):435-42.
    View in: PubMed
    Score: 0.005
  72. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005 Dec 20; 112(25):3823-32.
    View in: PubMed
    Score: 0.005
  73. Short-term effects of right-left heart sequential cardiac resynchronization in patients with heart failure, chronic atrial fibrillation, and atrioventricular nodal block. Circulation. 2004 Nov 30; 110(22):3404-10.
    View in: PubMed
    Score: 0.004
  74. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet. 2003 May; 72(5):1154-61.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.